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Mucin 1 (MUC1) is a cell surface protein overexpressed in breast cancer. Mesoporous silica 
nanoparticles (MSNs) loaded with safranin O, functionalized with aminopropyl groups and gated 
with the negatively charged MUC1 aptamer have been prepared (S1-apMUC1) for specific 
targeting and cargo release in tumoral versus non-tumoral cells. Confocal microscopy studies 
showed that the S1-apMUC1 nanoparticles were internalized in MDA-MB-231 breast cancer 
cells that overexpress MUC1 receptor with subsequent pore opening and cargo release. 
Interestingly, the MCF-10-A non-tumorigenic breast epithelial cell line that do not overexpress 
MUC1, showed reduced (S1-apMUC1) internalization. Negligible internalization was also 
found for S1-ap nanoparticles that contained a scrambled DNA sequence as gatekeeper. S2-
apMUC1 nanoparticles (similar to S1-apMUC1 but loaded with doxorubicin) internalized in 
MDA-MB-231 cells and induced a remarkable reduction in cell viability. Moreover, S1-
apMUC1 nanoparticles radio-labeled with 99mTc (S1-apMUC1-Tc) showed a remarkable tumor 
targeting in in vivo studies with MDA-MB-231 tumor-bearing Balb/c mice. 
KEYWORDS  
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BACKGROUND 
Nanotechnology offers myriads of possibilities of developing innovative materials with 
extended applications in almost countless scientific and technological fields.1 Perhaps one of the 
most promising applications of nanotechnology, in the form of smart nanomaterials, is related 
with nanomedicine.2,3 Among the realm of nanodispositives with powerful applications in 
medicine, those related with controlled release are among the most appealing. The possibility of 
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supplying certain drugs or active molecules and biomolecules into the site at which its action is 
required is expected to drastically reduce side effects.4 In order to achieve this task, drugs or 
bioactive agents are normally incorporated into nanomaterials.5 Moreover, these loaded 
nanocarriers can also be functionalized with targeting ligands that allow selective internalization 
in the cells in which their action is required.6  
Among the set of nanocarriers, mesoporous silica nanoparticles (MSNs) have been extensively 
used in recent years due to their remarkable properties, such as homogeneous pore size, large 
specific volume and area, good thermal stability, biocompatibility and easy functionalization.7,8 
Notwithstanding, perhaps the most appealing feature of MSNs as carriers is the possibility of 
functionalizing them with molecular/supramolecular ensembles on their external surface to 
develop gated materials, which ideally show “zero delivery”, yet release the payload on-
command in response to specific external stimuli. A number of gated MSNs able to deliver the 
payload with pH changes, redox reactions, light, magnetic fields, ultrasounds, temperature, 
polarity changes and presence of molecules or biomolecules have been recently described.9 
These gated materials have been mainly studied as drug delivery systems and for sensing and 
diagnostic applications.9-20 Among biomolecules, DNA and aptamers have been recently used as 
caps to develop gated materials for drug delivery and sensing.21-25 Moreover, certain aptamers 
can be used as targeting agents, which make them a valuable alternative to antibodies and 
peptides.26,27   
From another point of view, one of the most powerful in vivo imaging techniques is isotopic 
labeling.28 This technique consists in marking the (bio)-molecule or nanodevice that we wish to 
track with selected radionuclides. Decay in the radionuclide emits radiation that can be detected 
by signaling the presence of the labeled system. In nuclear medicine, a widely used technique to 
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detect radionuclides is single photon emission computed tomography (SPECT).29,30 Among 
various SPECT radionuclides, 99mTc has been extensively used to develop radiopharmaceuticals 
because of its ideal nuclear properties and easy low-cost availability.31-33 Recently certain 
SPECT radionuclides (99mTc and 188Re) have been incorporated into specific aptamers and 
evaluated for their clinical applicability.34-36 Some of those radionuclide-labeled aptamer probes 
have shown rapid accumulation rates in tumor, good targeting ability and fast clearance from 
blood. MSNs have also been radiolabeled with several radioisotopes by different approaches 
(e.g., direct adsorption onto surfaces, coating nanoparticles with poly(ethylene glycol) 
conjugated with marked antibodies, functionalizing the nanoparticle surface with t-cyclooctene 
derivatives that have undergone 3+2 cycloadditions with labeled tetraazines and grafting 
complexes through amidation reactions) and have been used for positron emission tomography 
(PET) and SPECT imaging.37-45 However, a typical drawback of some of these labeled systems is 
poor tumor accumulation.39,40 
MUC1 is a mucin glycoprotein expressed in the extracellular matrix by most glandular and 
ductal epithelial cells, and by several hematopoietic cell lineages.46 MUC1 is also highly 
expressed by the majority of human adenocarcinomas and its presence has been associated with 
poor clinical prognosis. MUC1 is shed in the bloodstream of adenocarcinoma patients and is the 
antigen in commercial serum tumor marker assays.47 The extracellular presentation of MUC1, its 
elongated structure and characteristic under-glycosylation patterns allow the protein core to be 
exposed in cancer cells, which thus make it a suitable target for immunotherapeutic and targeted 
radiotherapy approaches.48 In line with this, MUC1 aptamers (that bind ligands to the MUC1 
glycoprotein tumor marker) have been functionalized with commercially available chelators, 
radiolabeled with 99mTc and used in bio-distribution and imaging studies in xenografted MCF-7 
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tumor-bearing mice.49-51 MUC1 aptamers have also been grafted onto the external surface of 
silica nanoparticles labeled with fluorophores and the prepared nanodevices used to detect breast 
cancer cells.52  
Taking into account this information and based in our interest in preparing gated MSNs and 
applying them to controlled release and signaling applications,9,11 we show herein the synthesis, 
characterization, controlled release features and imaging properties of MSNs loaded with 
safranin O or with doxorubicin, capped with an aptamer targeting MUC1 glycoprotein. These 
nanoparticles released the entrapped dye/drug in the presence of DNAse I enzyme and were 
preferentially internalized by MDA-MB-231 (expresses glycoprotein MUC1 in the membrane) 
cancer cells. Moreover, 99mTc radiolabeled capped nanoparticles, injected into MDA-MB-231 
tumor-bearing Balb/c mice, showed remarkable accumulation in tumors in SPECT images. The 
same accumulation trend was observed in bio-distribution studies. 
 
Figure 1. (A) Synthetic route used to prepare S1-apMUC1, S2-apMUC1 and S1-apMUC1-Tc 
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MATERIALS AND METHODS 
Tumour xenograft models  
MDA-MB-231 cells (American Type Culture Collection, Manassas, VALLC) were cultured in 
RPMI (Gibco, Life technologies, MD, USA), supplemented with 10% of fetal bovine serum 
(Gibco, Life technologies, MD, USA) and 50 µg/mL of gentamicin (Gibco, Life technologies, 
MD, USA). Mycoplasma contamination in cultured cells was excluded using the Lonza 
Mycoplasma detection kit. Tumors were established by a subcutaneous injection of 2 x 106 
MDA-MB-231 cells on the backs of 6-week-old female Balb/c nude mice. Tumor size was 
monitored for 3 weeks and measured by a caliper. Tumor size before imaging was about 2 cm. 
Balb/c nude mice were bred at the animal facility of the Nuclear Energy Research Institute 
(IPEN). All the experiments complied with relevant laws and were approved by local animal 
ethics committees. Mice were observed 3 times a week to evidence any distress, ascites, 
paralysis or excessive weight loss. 
 
Cell culture studies 
Cells MDA-MB-231 were cultured in DMEM/F12 containing 10% FCS, 100 U/mL of 
penicillin and streptomycin, and MCF-10-A in and DMEM/F12 containing 100 U/mL of 
penicillin and streptomycin, 10% FCS, 10 µg/mL of insulin solution human recombinant from 
Saccharomyces cerevisiae, 0.5 µg/mL of hydrocortisone, 100 ng/mL of Cholera toxin from 
Vibrio cholerae and 20 ng/mL of EGF recombinant human protein solution. 
 
Cell viability studies 
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The toxicological profile of the S1-apMUC1 solid was studied in vitro in MDA-MB-231 and 
MCF-10-A cell lines. MDA-MB-231 and MCF-10-A were seeded in a 96-well plate and treated 
with different S1-apMUC1 concentrations (0, 25, 50, 100 and 200 µg/mL in PBS). Cells were 
incubated for 24 and 48h and the viability was determined adding the cell proliferation reagent 
WST-1 and for 1h. Finally, cell viability was measured at 595 nm in the Wallac Workstation. 
    
Cellular uptake studies  
To study the capacity of the S1-apMUC1 to internalize into the MDA-MB-231 cells, uptake 
studies were carried out. For this purpose, a solid containing covalently attached rhodamine and 
capped with the MUC1 aptamer was prepared (S-RhB-apMUC1) and internalization studies 
were performed by confocal microscopy with lysosome markers. MDA-MB-231 cells were 
seeded over glass coverslips at 300.000 cells/ml in 6-well assays plates and incubated at 37 ºC. 
The S-RhB-apMUC1 nanoparticles were added to cells at 50 µg/mL, lysotracker green DND-26 
was added at 0.2 µM, and cells were incubated for 1 h at 37 ºC. Then cells were washed several 
times with PBS. DNA marker, Hoechst 33342, was added at 1 µg/mL. Slides were visualized 
using a confocal microscope Leica TCS SP8 HyVolution II 
 
Controlled release of solid S1-apMUC1 triggered by the presence of MUC1 in cell lines   
Internalization and cargo delivery from S1-apMUC1 in MDA-MB-231 (that expressed high 
levels of MUC1) and MCF-10-A (that expressed low levels of MUC1) cells were studied by 
confocal microscopy. Both cells lines were seeded over glass coverslips at a cell density of 
250,000 cells/ml in 6-well assay plates and incubated at 37 ºC. The S1-apMUC1 nanoparticles 
were added to cells (100 µg/mL) and were incubated at 37 ºC for 1 h. Then cells were washed 
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several times with PBS. Finally, DNA marker Hoechst 33342 was added. Slides were visualized 
using a confocal microscope Leica TCS SP2 AOBS. Moreover, to further prove the specific S1-
apMUC1 nanoparticles MUC1-mediated cell uptake, experiments with a solid capped with a 
scrambled DNA sequence without any selectivity towards MUC1 receptor (solid S1-Ap) were 
performed. MDA-MB-231 cells were treated with S1-ap at 100 µg/ml. After 1 h of incubation, 
cells were washed with PBS and slides were prepared for confocal microscopy as described 
above.  
 
Anti-tumoral activity of S2-apMUC1  
In order to evaluate the effectiveness of MUC1-capped nanoparticles as drug delivery system, 
a solid loaded with doxorubicin (S2-apMUC1) was prepared. MDA-MB-231 and MCF-10-A 
cells were seeded in 96-well plate. Then, S2-apMUC1 solid was added at 50 and 100 µg/mL. 
After 30 min of incubation, cells were washed with PBS and new media added in each case and 
incubated for another 24 h. Doxorubicin-induced cell death was evaluated by adding the WST-1 
reagent for 1h and absorbance was measured at 595 nm.  
 
Bioluminescence and imaging  
Three female Balb/c nude mice aged 8-9 weeks with breast cancer in the right flank were used 
for bio-distribution and imaging (SPECT). The animals inducted with breast cancer were 
examined by bio-luminesce. Mice were administered D-luciferin (150 mg/kg, Promega) by 
intraperitoneal injection. Immediately after the D-luciferin injection, photons from each animal’s 
whole body were counted by the IVIS Spectrum imaging system (Xenogen/Caliper Life 
Sciences, CA) according to the manufacturer`s instructions. Data were analyzed by the Living 
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Image 4.3 software (Xenogen). Planar images were obtained 90 min after injecting the S1-
apMUC1-Tc nanoparticles (3.7 MBq in 0.2 mL) with a Millennium Gamma Camera (GE 
Healthcare, Cleveland, USA). Counts were acquired for 5 min in a 15% window centered at 140 
KeV. Images were processed using the OsiriX software, and regions of interest (ROIs) over the 
tumor were selected for specific analyses. Three inducted mice were imaged separately. 
 
Bio-distribution  
Mice were maintained at a controlled temperature (23 ºC ± 2) with water and food ad libitum. 
No sedative or anesthetic was used. Labeled samples (3.7 MBq/0.2 mL) were administered by 
intraocular (retro-orbital) injection. Mice were sacrificed by asphyxiation in a carbon dioxide gas 
chamber 120 min after administering the S1-apMUC1-Tc nanoparticles. Organs (brain, lungs, 
kidneys, stomach, small and large intestine, bladder, heart and blood pool) were removed, 
weighed, and the activity in each organ and blood was counted by a gamma counter (Perkin 
Elmer Wizard® 2470). The results were expressed as a percentage of the injected dose per organ. 




Design and synthesis of aptamer-capped nanoparticles 
MSNs were prepared in alkaline media following well-known procedures using n-
cetyltrimethylammonium bromide (CTAB) as directing agent to condense the inorganic 
precursor tetraethylortosilicate (TEOS).53 The obtained powder was washed and CTAB was 
removed by calcination. The pores of the calcined MSNs were loaded with safranin O and the 
external surface of the nanoparticles was functionalized with (3-aminopropyl) triethoxysilane 
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(solid S1). Aminopropyl moieties were positively charged at a neutral pH and they are known to 
display electrostatic and hydrogen bonding interactions with negatively charged aptamers. 
Therefore, the addition of an MUC1 aptamer to a suspension of S1 nanoparticles resulted in pore 
capping, which yielded the final material S1-apMUC1 (see Figure 1). The same procedure 
described above, but using doxorubicin instead of safranin O as cargo, was used for the 
preparation of S2 and S2-apMUC1 nanoparticles (see also Figure 1). S1-apMUC1 and S2-
apMUC1 nanoparticles were expected to be effectively internalized by cancer cells that 
overexpressed glycoprotein MUC1 and to deliver the cargo via the hydrolysis of the capping 
aptamer by DNAse enzymes. Moreover, we also labeled S1-apMUC1 with the 99mTc 
radioisotope to explore the potential use of these nanoparticles as radiopharmaceutical probe (S1-
apMUC1-Tc).  
 
Figure 2. Left: Powder X-ray diffraction patterns of MCM-41 nanoparticles as made (a), 
calcined MCM-41 nanoparticles (b) and solid S1 (c). Right: TEM images of the calcined MCM-
41 nanoparticles (d) and solid S1 (e). 
 
Characterization of gated MSNs  
c) S1
b) calcined MCM-41






The powder X-ray diffraction (PXRD) of the MCM-41 as-synthesized nanoparticles (curve a 
in Figure 2) showed four low-angle reflections, typical of a hexagonal mesoporous array that can 
be indexed as (100), (110), (200) and (210) Bragg peaks. The presence of the (100) reflection in 
the calcined MSNs (curve b in Figure 2) and in solid S1 (curve c in Figure 2) evidenced that the 
loading pores with safranin O and the further functionalization of the external surface with 
aminopropyl moieties did not modify the 3D mesoporous structure. Furthermore, the 
mesoporous structure was confirmed by transmission electron microscopy (TEM) in MSNs and 
S1 samples (Figure 2). TEM images also showed that the starting MSNs and solid S1 consisted 
of spherical particles with a diameter of ca. 100 nm. Dynamic light scattering measurements 
resulted in values of hydrodynamic diameters of 114 nm and 407 nm for the starting calcined 
MSNs and S1-apMUC1, respectively. Moreover, zeta potential values of -11.90, +3.02 and -
7.92 mV were obtained for the calcined MSNs, S1 and S1-apMUC1. 
N2 adsorption-desorption studies on the starting MSNs and S1 were carried out. For both 
materials, the pore volume was calculated by applying the Barret-Joyner-Halenda (BJH)54 model 
on the adsorption branch of the isotherm and the total specific surface was calculated by the 
Brunauer-Emmet-Teller (BET)55 model. The values obtained for the staring calcined MSNs and 
S1 are listed in Table 1. Moreover, the safranin O and aminopropyl contents on solid S1 were 
determined by thermogravimetric studies and elemental analyses, which amounted to 0.044 
(loading efficiency of 5.5%) and 1.821 mmol g-1, respectively. 
 
Table 1. BET-specific surface values, pore volumes and pore sizes calculated from the N2 
adsorption-desorption isotherms for calcined MSNs and S1. 
Solid SBET [m2 g-1] BJH pore size
[a,b] 
[nm] 
Total pore volume[a] 
[cm3 g-1] 
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[a] Pore volumes and pore sizes related only to interparticle mesopores. 
[b] Pore sizes estimated by the BJH model applied to the adsorption branch of the isotherm. 
 
Energy dispersive X-ray spectroscopy (EDX, 20 kV) studies on S1-apMUC1 showed the 
presence of phosphorus atoms (values of weight and the atom percentage of 0.36 and 0.19% 
respectively, see Supporting Information), which is in agreement with the capping of the 
nanoparticles with the MUC1 aptamer.  
 
In vitro safranin O release studies form S1-apMUC1 
Cargo release from the S1-apMUC1 nanoparticles alone and in the presence of DNAse I was 
studied. In a typical experiment, 100 µg of S1-apMUC1 were suspended in Tris buffer (20 mM 
Tris, pH 7.5; 37.5 mM MgCl2) and then separated into two aliquots. Only to one of the samples 
DNAse I (at the 10 U µL-1 concentration) was added. Both suspensions were stirred and aliquots 
were taken at scheduled times. These aliquots were centrifuged to remove the solid and the 
emission of the safranin O released at 585 nm (excitation at 520 nm) was measured. The 
obtained release profiles are shown in Figure 3. 
Calcined MSNs 1195 2.51 0.961 
S1 66 - 0.036 
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Figure 3. In vitro release profiles of safranin O from solid S1-apMUC in the absence (a) and 
presence (b) of DNAse I in Tris (20 mM pH 7.5) that contained MgCl2 (37.5 mM). 
 
Cell viability studies 
In order to discard any toxicity associated with the mesoporous scaffold or the MUC1 coating 
shell, cell viability assays using S1-apMUC1 nanoparticles at different concentrations were 
evaluated by the WST-1 assay (see Supporting Information). The results demonstrated that S1-
apMUC1 nanoparticles were well-tolerated by MDA-MB-231 and MCF-10-A cell lines at 
concentrations up to 200 μg/mL after 24 and 48 h of exposure.  
Cellular uptake studies  
Uptake studies with cells were carried out with nanoparticles S-RhB-apMUC1, which are 
similar to S1-apMUC1 but containing rhodamine B covalently anchored through the formation 
of thiourea bonds to the silica surface. Internalization studies in MDA-MB-231 cells were 




Figure 4. Internalization studies of S-RhB-apMUC1 in MDA-MB-231 cells. Cells were 
incubated for 1 h in the presence of S-RhB-apMUC1 solid (50 µg/mL) and lysosomes were 
marked with lysotracker green DND-26 (0.2µM). The internalization of the nanoparticles was 
followed by rhodamine B fluorescence (red) in the presence of the lysosome probe Lysotracker 
green DND-26 (green) and DNA probe Hoechst 33342 (blue). The presence of a yellow signal in 
the merged image evidences a high co-localization of the S-RhB-apMUC1 nanoparticles and the 
lysosomes.   
 
Controlled release performance of solid S1-apMUC1 in cell lines   
The controlled cargo release from S1-apMUC1 nanoparticles in cells was assessed by 
confocal microscopy studies. The MDA-MB-231 and MCF-10-A cell lines were incubated with 
the S1-apMUC1 nanoparticles for 1 h and safranin O-associated fluorescence was measured (see 
Figure 5A and C respectively). Results show a significantly higher release of safranin in MDA-
MB-231 tumor cells, which overexpress MUC1, versus non-tumor MCF-10-A cells.  
Moreover, the MUC1-mediated specific uptake of the S1-apMUC1 nanoparticles was also 
assessed using solid S1-ap, loaded with safranin O, but capped with a scrambled DNA sequence 
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(with no binding specificity with MUC1). MDA-MB-231 cells were treated with S1-ap and after 
1 h of incubation the internalization was followed by safranin O-associated fluorescence (see 
Figure 5B). Quantification of the fluorescence associated with safranin O was determined for 





Figure 5. Specific targeting of S1-apMUC1. Cellular uptake of S1-apMUC1 A) and S1-ap B) 
in the MDA-MB-231 cells. C) cellular uptake of S1-apMUC1 in MCF-10-A cells. Both cell 
lines were incubated for 1 h in the presence of S1-apMUC1 (100 µg/mL) (A and C) and S1-ap 
(100 µg/mL) (B). The internalization of the nanoparticles was followed by safranin O-associated 
fluorescence (red) in the presence of DNA marker Hoechst 33342 (blue). D) Quantification of 
the safranin O-associated fluorescence intensity for the different treatments. Quantification in 
MDA-MB-231 cells (grey bars) in the presence or absence of S1-ap and S1-apMUC1 
nanoparticles. In black bars quantification of safranin O associated fluorescence in MFC-10-A 
cells in the absence or presence of S1-apMUC1 nanoparticles. Three independent experiments 
were done, which gave similar results. Data are expressed as mean ± s. Statistically significant 
differences were found among the different treatments in the case of MDA-MB-231 in the 
presence of S1-apMUC1 nanoparticles when paired t Student tests were applied (p < 0.0001).  
 
Anti-tumoral assays with S2-apMUC1  
In order to demonstrate the potential applicability of the MUC1 capped nanoparticles for drug 
delivery, a new material based on MSNs loaded with doxorubicin and capped with the MUC1 
aptamer (S2-apMUC1) was prepared. MDA-MB-231 and MCF-10-A cells were treated with 50 
and 100 µg/mL of S2-apMUC1 and cell viability assays were carried out (Figure 6). Release of 
the doxorubicin cargo induced cell death at nanoparticle concentrations where S1-apMUC1 was 
innocuous. Moreover, the cell death induction capability of S2-apMUC1 in the tumor cell line 


























Figure 6. S2-apMUC1 induces cell death in breast cancer cells. Cell viability assays of S2-
apMUC1 nanoparticles in MDA-MB-231 (gray) and MCF-10-A (black) cells. S2-apMUC1 
nanoparticles were added at 50 and 100 µg/ml and, after 30 min of incubation, cells were washed 
with PBS and new media added in each case and incubated for another 24 h. Then, doxorubicin 
activity was evaluated by adding the WST-1 reagent for 1 h and absorbance was measured at 595 
nm. Three independent experiments were done, which gave similar results. Data are expressed as 
mean ± s. Statistically significant differences were found among the different treatments when 
paired t Student tests were applied (p < 0.0001) between the MDA-MB-231 treated at 50 and 100 
µg/ml with S2-apMUC1 nanoparticles and the untreated cells (#), and  significant differences 
were found among the treatments between MDA-MB-231 and MCF-10-A cells (***).  
 
Radiolabeling and imaging studies  
In order to take a step forward and to impart the MUC1 capped nanoparticles with diagnostic 
features, we carried out the labelling of S1-apMUC1 with the 99mTc radioisotope. 99mTc is a 
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metastable isomer of 99Tc used as a radioactive tracer in diagnostic nuclear medicine procedures. 
It emits easily detectable 140.51 keV gamma rays and has a half-life of 6.02 h.56  
In a typical procedure, S1-apMUC1 (150 µg) were incubated with SnCl2 as the reducing agent 
and with Na99mTcO4 (300 µL with 100 µCi) for 20 min at room temperature. This resulted in the 
production of 99mTc that labeled the nanoparticles (S1-apMUC1-Tc). The small quantity of the 
prepared labeled solid precluded complete characterization by standard techniques. Nevertheless, 
the correct radiolabeling of MSNs was assessed by thin layer chromatography (TLC) using 
acetone as the mobile phase (see Supporting Information).  
The labeled S1-apMUC1-Tc nanoparticles were tested for in vivo imaging using SPECT. For 
this purpose, a 6-week-old female MDA-MB-231 tumor-bearing Balb/c mice model was used. 
S1-apMUC1-Tc (3.7 MBq/0.2 mL) was administered to mice by intraocular (retro-orbital) 
injection. In vivo static planar images were obtained with a Millennium Gamma Camera after 90 
min in a window centered at 140 keV. The obtained images are shown in Figure 7. As seen in 
Figures 7A and 7C, the MUC1-positive tumor region showed strong signals (white spots) due to 
the accumulation of S1-apMUC1-Tc nanoparticles at 90 min post-injection. Besides, SPECT 
images of the organs and tumor excised from the S1-apMUC1-Tc treated mice after 120 min 
post-injection were taken (see Supporting Information). Strong signals were observed in kidneys, 
liver and tumor indicating the preferential accumulation of S1-apMUC1-Tc nanoparticles into 
these organs.   
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Figure 7. A) Static planar SPECT image of the MDA-MB-231 tumor-bearing Balb/c mice model 
after administering the S1-apMUC1-Tc nanoparticles (3.7 MBq/0.2 mL) at 90 min post-
injection. B) Bioluminescence images from mice on day 21 after the intra-ventricular injection of 
the MDA-MB-231 cancer cells that reveal tumoral lesions. C) Static planar SPECT inverse 
image of the MDA-MB-231 tumor-bearing Balb/c mice model after administering the S1-
apMUC1-Tc nanoparticles (3.7 MBq/0.2 mL) at 90 min post-injection. 
 
Bio-distribution assays 
For the bio-distribution assays, mice were sacrificed 120 min after the injection of S1-
apMUC1-Tc, organs were removed, weighed and activity was counted with a gamma counter. 
The results obtained as a percentage of injected dose per gram and per organ are shown in Figure 
8A and 8B respectively. The same experiments were carried out with bare MSNs labelled with 
99mTc in healthy and MDA-MB-231 tumor-bearing Balb/c mice as negative and positive 
controls respectively (see Supporting Information). 
 
 
A) B) C) 
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Figure 8. Bio-distribution profile of the S1-apMUC1-Tc nanoparticles in MDA-MB-231 tumor-
bearing Balb/c mice (n = 3) expressed as (A) dose per gram of organ, (B) dose per organ. 
 
DISCUSSION 
PXRD of S1 evidenced that the process of loading the pores with safranin O and the 
functionalization of the external surface with aminopropyl groups did not modify the 3D 




nanoparticles confirmed the presence of the mesoporous structure (Figure 2). The typical 
channels of the mesoporous silica network were visualized as alternate black and white stripes.  
Adsorption-desorption isotherms of calcined MSNs showed a typical curve for mesoporous 
silica (see Supporting Information), which consisted in an adsorption step at intermediate P/P0 
value (0.1–0.3). Narrow BJH pore distribution and absence of a hysteresis loop within this 
interval suggested the existence of uniform cylindrical mesopores (pore diameter of 2.10 nm, 
pore volume of 0.26 cm3 g–1, calculated on the adsorption branch of the isotherm). Pore diameter 
was estimated by analyzing the TEM images that agreed with this value. After applying the BET 
model, a value of 1195 m2 g–1 was obtained for the total specific surface. The N2 adsorption-
desorption isotherm of solid S1 was typical of mesoporous systems with filled mesopores, and 
both the pore volume (0.036 cm3 g-1) and the specific surface area (66 m2 g-1) drastically 
diminished (see Supporting Information). This reduction in the BET surface, compared with that 
of the starting MSNs, was attributed to loading pores with safranin O and surface 
functionalization with aminopropyl moieties. 
Calcined MSNs showed a negative zeta potential of -11.90 mV due to the silanolate groups, 
whereas S1 had a positive zeta potential (3.02 mV) due to the presence of the positively charged 
safranin O (in the inner of the pores) and aminopropyl moieties (grafted onto the external surface 
of the nanoparticles). Finally, a marked reduction in the value of zeta potential (-7.92 mV) was 
observed for S1-apMUC1 nanoparticles ascribed to pore capping with the negatively charged 
MUC1 aptamer. 
Dealing with controlled release studies, it was observed that S1-apMUC displayed a poor 
safranin O release (ca. 10% in the first 30 min and reached 20% after 60 min) in the absence of 
DNAse I (see Figure 3). However when the enzyme was present, a remarkable fast safranin O 
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delivery took place (ca. 90% of the total amount released was found after ca. 30 min). The 
observed payload release was directly related with the DNAse I-induced hydrolysis of the MUC1 
aptamer that allowed pore opening and dye delivery. 
After conducting studies on the effective safranin O release from S1-apMUC1 in the presence 
of DNAse I, our next goal was to prove the possible use of these aptamer-capped nanoparticles 
as delivery system in cell models. First, cell viability studies using S1-apMUC1 nanoparticles at 
different concentrations were carried out by the WST-1 assays. S1-apMUC1 nanoparticles were 
non-toxic for MDA-MB-231 and MCF-10-A cells at concentration up to 200 µg/mL after 24 and 
48 h of incubation (see Supporting Information). Moreover, confocal microscopy analyses were 
used to evaluate whether the nanoparticles were internalized in MDA-MB-231 cells by tracking 
rhodamine associated fluorescence in S-RhB-MUC1 nanoparticles. A dotted pattern of a 
rhodamine fluorescent signal associated with intracellular vesicles was observed (Figure 4, 
central panel), which suggests the internalization of nanoparticles. Moreover, the cells were 
marked with Lysotracker green DND-26, and co-localization of the nanoparticles with lysosomes 
was confirmed via the presence of a yellow signal in merged images (Figure 4 right panel).   
Next, the uptake of S1-apMUC1 nanoparticles by MDA-MB-231 (which expresses high levels 
of glycoprotein MUC1 in its membrane) and MCF-10-A (which showed low levels of MUC1) 
cancer cells was studied (Figure 5). MDA-MB-231 cells internalized the S1-apMUC1 
nanoparticles more efficiently than the MCF-10-A cells. In fact a strong red fluorescence of the 
released safranin O was observed in the cytoplasm for the MDA-MB-231 cells, whereas the 
signal in the MCF-10-A cells was significantly lower under the same conditions (see Figure 5A 
and C). These differences could be explained by a greater internalization of S1-apMUC1 in the 
MDA-MB-231 cells, which supports the specific targeting of the nanoparticle mediated by 
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MUC1. Quantification of the fluorescence associated with safranin O was determined for each 
treatment (see also Figure 5D). A very weak safranin O emission for the MCF-10 cells treated 
with the S1-apMUC1 nanoparticles was observed. In contrast, a marked safranin O associated 
fluorescence (4-fold enhancement compared to that obtained for the MCF-10-A cells) was found 
for MDA-MB-231 cells treated with S1-apMUC1.  
The key role played by MUC1 aptamer in the preferential internalization of S1-apMUC1 
nanoparticles by MDA-MB-231 cells was assessed by testing the cellular uptake of solid S1-ap 
(loaded with safranin O and capped with a scrambled DNA sequence). As could be seen in 
Figure 5B negligible fluorescence associated with safranin O was observed in MDA-MB-31 cells 
incubated with S1-ap nanoparticles. Besides, this low safranin O emission when MDA-MB-31 
cells were treated with S1-ap nanoparticles, clearly indicated that differences observed with S1-
apMUC1 under similar conditions are not due to different endocytosis ratios but most likely 
ascribed to the higher overexpression of MUC1 receptor in MDA-MB-31 cells. 
Once demonstrated the role played by the MUC1 aptamer in the enhancement of the 
internalization of S1-apMUC1, our next purpose was to test the possible use of these 
nanoparticles as drug delivery carriers. For this purpose, doxorubicin was selected as cargo for 
the preparation of solid S2-apMUC1. Doxorubicin is employed in the treatment of various types 
of cancer. However, the non-specific cellular internalization of this drug is associated to major 
secondary effects (such as cardio- and nephrotoxicity).57 Loading doxorubicin in nanoparticles 
has been reported to be an interesting strategy to decrease the unwanted secondary effects, 
thereby increasing the efficiency of this drug.58 Internalization and cargo delivery of S2-
apMUC1 were tested in MDA-MB-231 and MCF-10-A cells. Figure 6 shows viability studies of 
cells treated with the S2-apMUC1 nanoparticles A remarkably decrease in the viability of 
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MDA-MB-231 cells, which overexpressed MUC1 glycoprotein, upon treatment with S2-
apMUC1 nanoparticles, was observed. This decrease is associated to doxorubicin release due to 
preferential uptake by MDA-MB-231 cells and subsequent hydrolysis of the MUC1 cap. In 
contrast, in the case the MCF-10-A cells (which lower expression of the MUC1 glycoprotein) the 
cell viability was ca. 80% indicating a poor doxorubicin release inside these cells.  
Then, S1-apMUC1 nanoparticles were labelled with 99mTc and their targeting ability was 
studied in MDA-MB-231 tumor-bearing Balb/c mice. In vivo imaging using SPECT the MUC1-
positive tumor region showed strong signals due to the accumulation of S1-apMUC1-Tc 
nanoparticles at 90 min post-injection (Figure 7A). This is a remarkable result which revealed 
that the accumulation of S1-apMUC1-Tc nanoparticles in tumors was significantly larger 
compared with the bioaccumulation of the free MUC1 aptamer labeled with 99mTc (vide infra).49-
51 Marked accumulation was also observed in the upper part of the image, which correlated with 
the injection site (retro-orbital). Figure 7B depicts the bioluminescence imaging that indicates the 
tumor position, which correlated with planar images; accumulation of the S1-apMUC1-Tc 
nanoparticles by the tumor, as observed by comparing bioluminescence (red and yellow spots in 
Figure 7B) and planar images. The high S1-apMUC1-Tc accumulation in the tumor was 
suggested to be partly due to the interaction of the MUC1 aptamer in the functionalized MSNs 
with the MUC1 glycoprotein overexpressed in the MDA-MB-231 cancer cells. This suggests that 
S1-apMUC1-Tc is a potential candidate for cancer diagnosis by imaging. Besides, SPECT 
images of kidneys, liver and tumor excised from the S1-apMUC1-Tc-treated mice after 120 min 
post-injection showed strong signals (see Supporting Information) indicating accumulation of 
S1-apMUC1-Tc nanoparticles in these organs. 
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Bio-distribution profiles (Figure 8) of the S1-apMUC1-Tc nanoparticles showed a significant 
uptake of the nanodevice by tumoral lesions (ca. 20% ID/g and 15% ID). This result once again 
suggested the targeting abilities of the S1-apMUC1-Tc nanoparticles towards the MUC1 
glycoprotein overexpressed in the MDA-MB-231 cancer cells. A certain uptake of the labeled 
nanoparticles by lungs and intestine was observed. These results were expected since the MUC1 
glycoprotein ubiquitously spreads throughout the body, especially to intestine and lungs. 
However, accumulation in tumor was remarkably larger. Besides, the excellent uptake of the S1-
apMUC1-Tc nanoparticles by kidneys is a desirable feature since radioactive materials have to 
be excreted from the body quickly and efficiently. The activity observed in bladder is in 
accordance with the finding of nanoparticles in kidneys and indicated a non-reabsorption effect 
of the nanomaterial in kidneys. Another remarkable feature of the bio-distribution data is the low 
uptake percentage observed in the liver and spleen. This low uptake for these two organs 
suggested that the S1-apMUC1-Tc nanoparticles were able to avoid the mononuclear phagocytic 
system (MPS). This fact was corroborated by presence of radiation in blood, which suggested 
that nanoparticles have a certain affinity for blood proteins (e.g., albumin) and, consequently, a 
long-lasting circulation, which agreed with a certain signal in the heart. Finally, it is important to 
note the negligible uptake by the brain, which is quite a desirable feature for radiopharmaceutical 
materials and radioactive drugs. 
Bio-distribution profiles of 99mTc labeled MSNs (without the MUC1 aptamer) in healthy and 
MDA-MB-231 tumor-bearing Balb/c mice as negative and positive controls respectively were 
also obtained (see Supporting Information). 99mTc labeled MSNs accumulated in kidneys and 
liver in healthy mice. Besides, in MDA-MB-231 tumor-bearing Balb/c mice, bio-distribution 
profile showed accumulation of nanoparticles in kidneys, bladder, stomach and liver. However, 
 27 
the most remarkable feature of the positive control is the nearly negligible tumor accumulation of 
the 99mTc labeled MSNs. This strongly contrast with the results when using S1-apMUC1-Tc 
nanoparticles. This indicated the crucial role played by MUC1 aptamer in the observed tumor 
accumulation of S1-apMUC1-Tc. MUC1 aptamer acts not only as gatekeeper but also as 
targeting unit directing S1-apMUC1-Tc nanoparticles to MDA-MB-231 cells in an in vivo 
model.  
It is noteworthy that the bio-distribution results obtained with the S1-apMUC1-Tc 
nanoparticles showed remarkable performance in terms of relative accumulation in tumors 
compared to other systems; e.g., several PET/SPECT nanoparticle-based materials (that involve, 
or not, aptamer bio-direction) or others based on radiolabeled MUC1 aptamers or antibodies, or 
when compared to other aptamer-based radio-diagnosis systems. For instance, it has been 
reported that MUC1 aptamers functionalized with a cyclen macrocycle and labeled with 99mTc 
show minor tumor accumulation (0.01-0.12% ID/g), with larger amounts located in liver and 
kidneys.49 Similarly, radiolabeled bare MSNs have been reported to display a relatively low 
accumulation of the injected dose in tumors (5.4% ID/g).37 These results demonstrated that 
radiolabeling MUC1 aptamer-bearing MSNs offers remarkable performance in imaging terms 
compared with using the aptamer or MSNs alone. We believe that this approach is general and 
can be used to design other similar nanoparticles for imaging applications. 
In summary, we have designed, synthesized and characterized MUC1 aptamer-capped MSNs 
able to preferentially release an entrapped cargo (safranin O and doxorubicin) in MDA-MB-231 
cells that overexpress glycoprotein MUC1. Moreover, nanoparticles were also radiolabeled with 
99mTc and used for bio-imaging applications. S1-apMUC1 nanoparticles showed poor cargo 
release in the absence of DNAse I, whereas marked safranin O delivery took place when the 
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enzyme was present. Confocal microscopy studies revealed that the S1-apMUC1 nanoparticles 
were significantly uptaken by MDA-MB-231 cells and were able to deliver safranin O, whereas 
a remarkably lower cargo delivery was found for control MCF-10-A cells. Besides, S2-apMUC1 
nanoparticles were also preferentially internalized by MDA-MB-231 cells and a marked 
reduction in viability was observed related with the release of the entrapped doxorubicin. The 
nanoparticles labeled with the 99mTc radioisotope (S1-apMUC1-Tc) were used in the radio-
imaging studies on MDA-MB-231 tumor-bearing Balb/c mice. Remarkable tumor signaling and 
accumulation were observed. S1-apMUC1-Tc displayed well-enhanced tumor signaling when 
compared with other studies in which the MUC1 aptamer or the bare MSNs were also labeled 
with 99mTc. These results indicated that the combination of MSNs capped with aptamers and 
labeled with radionuclides is a promising candidate for theranostic applications (delivery + 
imaging). We believe that the results shown herein open up a wide range of new possibilities to 
develop smart innovative drug delivery and diagnostic nanodevices based on combination of 
capped mesoporous hybrid materials and radiopharmaceuticals. 
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